BG Medicine Obtains CE Mark for CardioSCORE(TM) Test in Europe

BG Medicine Obtains CE Mark for CardioSCORE(TM) Test in Europe

December 11, 2012

Innovative Blood Test for the Prediction of Major Cardiovascular Events Expected to Launch in the First Half of 2013

Eleven Biotherapeutics Initiates Phase 1b Clinical Study of EBI-005, a Novel, Topically-delivered IL-1 Inhibitor Protein for the Treatment of Dry Eye Disease

Eleven Biotherapeutics Initiates Phase 1b Clinical Study of EBI-005, a Novel, Topically-delivered IL-1 Inhibitor Protein for the Treatment of Dry Eye Disease

December 10, 2012

Follows Successful Completion of Phase 1a Clinical Study

Lead Candidate from Eleven’s AMP-Rx Product Engine for First-of-a-Kind Protein Therapeutics

T2 Biosystems Presents Data on Rapid and Direct Hemostasis Monitoring at ASH 2012

T2 Biosystems Presents Data on Rapid and Direct Hemostasis Monitoring at ASH 2012

December 10, 2012

T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the presentation of data on T2Hemostasis, the first system capable of rapidly characterizing key coagulation, platelet and other hematologic factors directly from whole blood on a single, compact instrument. The data were presented by researchers from the University of Pennsylvania at the 54th Annual Meeting of the American Society for Hematology (ASH) in Atlanta, GA.

Moderna Announces $40 Million In Financing To Advance Development Of New Biotherapeutic Modality: Messenger RNA Therapeutics™

Moderna Announces $40 Million In Financing To Advance Development Of New Biotherapeutic Modality: Messenger RNA Therapeutics™

December 6, 2012
Company announces appointment of Executive Leadership Team and Scientific Advisory Board
 

Governor Patrick Kicks Off Water Industry’s Trade Mission to Israel

Governor Patrick Kicks Off Water Industry’s Trade Mission to Israel

November 28, 2012

Delegation Comprised of Business, Government and Academic Leaders

Selecta Biosciences, Inc.

Selecta Biosciences and Sanofi Sign Global Collaboration to Develop Antigen-Specific Immunotherapies for up to Three Allergy Indications Based on Selecta’s Synthetic Vaccine Particle Technology

Selecta Biosciences and Sanofi Sign Global Collaboration to Develop Antigen-Specific Immunotherapies for up to Three Allergy Indications Based on Selecta’s Synthetic Vaccine Particle Technology

November 28, 2012
  • Collaboration starts with immunotherapy for life-threatening food allergies
  • Novel therapies engineered to produce immune tolerance for two additional antigens to abate allergic immune response in people with severe allergies
TransMedics, Inc.

UCLA performs first 'breathing lung' transplant in United States

UCLA performs first 'breathing lung' transplant in United States

November 26, 2012

Experimental technology could transform field of lung transplantation

TransMedics, Inc. Secures $36 Million Round of Financing

TransMedics, Inc. Secures $36 Million Round of Financing

November 27, 2012

— /PRNewswire/ -- TransMedics, Inc., the global leader in organ preservation technology, announced the closing of a $36 million financing round led by Abrams Capital with the participation of existing investors including Flagship Ventures, Hercules Technology Growth Capital and Kleiner Perkins Caufield & Byers.

bioMérieux and Quanterix Sign Strategic Partnership in Ultrasensitive and Multiplex Immunoassays

bioMérieux and Quanterix Sign Strategic Partnership in Ultrasensitive and Multiplex Immunoassays

November 15, 2012

Marcy l’Etoile (France) and Lexington, MA (U.S.) – November 15, 2012bioMérieux and Quanterix announced today that they have entered into a strategic agreement that gives bioMérieux worldwide exclusive rights to Quanterix’s Simoa technology in clinical laboratories and for industrial applications. Under the agreement, Quanterix will deliver a new instrument and consumables based on its Simoa technology. bioMérieux will develop ultra-sensitive and multiplex assays on the platform.

T2 Biosystems Announces Issuance of Patents Covering T2MR Direct Detection Technology

T2 Biosystems Announces Issuance of Patents Covering T2MR Direct Detection Technology

November 14, 2012

LEXINGTON, Mass., Nov 14, 2012 (BUSINESS WIRE) -- T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the U.S. Patent and Trademark Office has issued two patents adding depth and breadth to the Company's intellectual property portfolio. These patents cover both the device and methods related to the Company's flagship T2Candida assay and the detection of additional biological analytes, including specific drug and biomarker targets, in biological samples using the T2MR platform.